Clinical trials: Demyelinating Disease
Relapsing Remitting Multiple Sclerosis
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
This study was to find out if patients with Relapsing Remitting Multiple Sclerosis treated with Interferon beta-1a had an improved quality of life after treatment with Interferon beta-1a
- Trial name
- FLAIR (NCT00534261)
- Testing
- Interferon beta-1a
- Where
- 3 sites in Belgium, Luxembourg and 1 more
- Volunteers
- 284 people
- Sponsor
- Biogen
Secondary Progressive Multiple Sclerosis (SPMS)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
- Trial name
- NCT04593927
- Testing
- Mayzent
- Where
- 174 sites in Japan
- Volunteers
- 451 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report…
- Trial name
- NCT06460324
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF)…
- Trial name
- IMPROVE (NCT00441103)
- Testing
- Rebif® New Formulation (IFN-beta-1a, RNF)
- Volunteers
- 180 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
A Study for Patients With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.
- Trial name
- MINDSET01 (NCT00869986)
- Testing
- dirucotide
- Where
- 6 sites in Bulgaria, Poland and 4 more
- Volunteers
- 218 people
- Sponsor
- Eli Lilly and Company
Infantile Refsum's Disease, Zellweger Syndrome
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II.
- Conditions
- Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders
- Trial name
- NCT00007020
- Testing
- Cholic Acids
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
This study will investigate how 3 new types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01424462
- Testing
- A, B, C
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg…
- Trial name
- NCT01185821
- Testing
- BAF312
- Where
- 46 sites in United States, Canada and 10 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is…
- Trial name
- NCT06133049
- Testing
- Ozanimod, Select DMTs other than ozanimod, No DMTs
- Where
- United States
- Volunteers
- 2,961 people
- Sponsor
- Bristol-Myers Squibb
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
- Trial name
- ENABLE (NCT06433752)
- Testing
- No Intervention
- Where
- 113 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,000 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Remitting Multiple Sclerosis
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs.
- Trial name
- EPOC (NCT01317004)
- Testing
- Fingolimod, Standard MS DMT
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Pelizaeus-Merzbacher Disease
Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects
The purpose of this study is to determine the safety and preliminary effectiveness of human central nervous system stem cells (HuCNS-SC®) transplantation in patients with Connatal Pelizaeus-Merzbacher Disease (PMD).
- Trial name
- NCT01005004
- Testing
- HuCNS-SC cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- StemCells, Inc.
Relapsing-remitting Multiple Sclerosis (RRMS)
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
- Trial name
- NCT06700343
- Testing
- Ocrelizumab (US), Ocrelizumab (EU), ABP 692
- Where
- 109 sites in United States, Belgium and 20 more
- Volunteers
- 152 people
- Sponsor
- Amgen
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®).
- Trial name
- CARE-MS I (NCT00530348)
- Testing
- Alemtuzumab, Interferon beta-1a
- Where
- 101 sites in United States, Argentina and 14 more
- Volunteers
- 581 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast.
- Trial name
- NCT00469378
- Testing
- firategrast
- Where
- 10 sites in Belgium, Czechia and 3 more
- Volunteers
- 46 people
- Sponsor
- GlaxoSmithKline
Relapsing Multiple Sclerosis (RMS)
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to…
- Trial name
- NCT04878211
- Testing
- Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Study of Oral Fampridine-SR in Multiple Sclerosis
To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT00127530
- Testing
- Fampridine-SR
- Where
- 34 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of…
- Trial name
- M22 (NCT01803867)
- Testing
- rHIgM22
- Where
- 17 sites in United States
- Volunteers
- 72 people
- Sponsor
- Acorda Therapeutics
Progressive Multifocal Leukoencephalopathy
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including…
- Trial name
- NCT03399981
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 80,327 people
- Sponsor
- Biogen
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people…
- Trial name
- XPERT (NCT07540221)
- Testing
- Gamunex-C, Xembify
- Where
- 15 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.